1013 related articles for article (PubMed ID: 26457017)
21. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.
Yao S; Zhang J; Chen H; Sheng Y; Zhang X; Liu Z; Zhang C
J Histochem Cytochem; 2013 Sep; 61(9):639-48. PubMed ID: 23686365
[TBL] [Abstract][Full Text] [Related]
23. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network.
Borges KA; Dai J; Parikh ND; Schwartz M; Nguyen MH; Roberts LR; Befeler AS; Srivastava S; Rinaudo JA; Feng Z; Marrero JA; Reddy KR
Contemp Clin Trials; 2019 Jan; 76():49-54. PubMed ID: 30439517
[TBL] [Abstract][Full Text] [Related]
24. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
Carr BI; Guerra V
Dig Dis Sci; 2016 Mar; 61(3):937-47. PubMed ID: 26576554
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis.
He S; Zhang DC; Wei C
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):426-34. PubMed ID: 25746139
[TBL] [Abstract][Full Text] [Related]
26. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
27. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Fujikawa T; Shiraha H; Yamamoto K
Acta Med Okayama; 2009 Dec; 63(6):299-304. PubMed ID: 20035286
[TBL] [Abstract][Full Text] [Related]
28. Squamous cell carcinoma antigen in hepatocellular carcinoma: Ready for the prime time?
Montagnana M; Danese E; Lippi G
Clin Chim Acta; 2015 May; 445():161-6. PubMed ID: 25840050
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma, a unique tumor with a lack of biomarkers.
Debes JD; Carrera E; Mattos AZ; Prieto JE; Boonstra A;
Ann Hepatol; 2019; 18(6):786-787. PubMed ID: 31494068
[TBL] [Abstract][Full Text] [Related]
30. New frontiers in biomarkers for hepatocellular carcinoma.
Giannelli G; Antonaci S
Dig Liver Dis; 2006 Nov; 38(11):854-9. PubMed ID: 16782417
[TBL] [Abstract][Full Text] [Related]
31. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study.
Biasiolo A; Trotta E; Fasolato S; Ruvoletto M; Martini A; Gallotta A; Fassina G; Angeli P; Gatta A; Pontisso P
Dig Liver Dis; 2016 Feb; 48(2):197-202. PubMed ID: 26614642
[TBL] [Abstract][Full Text] [Related]
32. New serum markers of hepatocellular carcinoma.
Masuzaki R; Karp SJ; Omata M
Semin Oncol; 2012 Aug; 39(4):434-9. PubMed ID: 22846860
[TBL] [Abstract][Full Text] [Related]
33. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
34. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
[TBL] [Abstract][Full Text] [Related]
35. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
36. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review).
Reichl P; Mikulits W
Oncol Rep; 2016 Aug; 36(2):613-25. PubMed ID: 27278244
[TBL] [Abstract][Full Text] [Related]
38. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
39. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
Inagaki Y; Tang W; Makuuchi M; Hasegawa K; Sugawara Y; Kokudo N
Liver Int; 2011 Jan; 31(1):22-35. PubMed ID: 20874725
[TBL] [Abstract][Full Text] [Related]
40. [Expression of glypican-3, hepatocyte antigen, alpha-fetoprotein, CD34 and CD10 in hepatocellular carcinoma: a clinicopathologic analysis of 375 cases].
Du JL; Wang YL; Shi HY; Guo AT; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):309-13. PubMed ID: 22883669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
